Acquisition Combines Hims & Hers’ Leading Wellness Platform with YourBio’s Patented, Virtually Painless Micro-Needle Technology to Redefine the Future of Blood Sampling
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio’s advanced blood sampling devices, the acquisition will help accelerate efforts to redefine and modernize the overall blood collection experience, making pain-free blood sampling the new standard.
YourBio Health develops technologies designed to simplify the process and expand when, where, and how blood samples can be collected—including beyond traditional clinic settings. Its TAP® device, built on HALO™ technology, uses bladeless microneedles thinner than an eyelash to produce high-quality capillary blood samples in seconds, without the pain or complexity of traditional methods, like fingerstick or venipuncture. Developed over years of extensive engineering, the TAP device and underlying HALO system are protected by a robust portfolio of patents covering state-of-the-art microtechnology design, sample handling, and device integration.
“The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human,” said Andrew Dudum, founder and CEO of Hims & Hers. “YourBio’s patented TAP and HALO technologies represent major advancements in user experience and design, and we’re excited to bring them into the Hims & Hers ecosystem.”
“YourBio’s HALO and TAP technologies are ushering in some of the most significant scientific advancements in the blood collection space in decades,” said Dr. Michael Mina, Chief Scientific Officer at YourBio Health. “By using micro-needles thinner than an eyelash, these systems produce high-quality blood samples with essentially no discomfort. This technology has the potential to change how people engage with routine blood collection – replacing long waits and painful needles with a far more convenient, user-friendly experience.”
“For decades, blood sampling has remained largely unchanged—forcing patients and healthcare providers through an inefficient process that causes pain and discomfort, heightens anxieties, and often takes more blood than is necessary,” said Paul Owen, CEO of YourBio Health. “By rethinking every aspect of the experience—from comfort and design to accessibility—we’re reimagining what the modern blood collection process can and should look like.”
With this acquisition, Hims & Hers will bring into its portfolio what it believes to be the most advanced, pain-free blood sampling technology to date, fueling its in-house innovation engine and redefining what’s possible in user-centric blood sampling. Dr. Michael Mina and Paul Owen will also join the Hims & Hers team, supporting the company’s efforts to drive the customer experience forward.
The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions. Consideration is comprised entirely of cash funded from Hims & Hers’ balance sheet.
For more information, please visit www.hims.com and www.yourbiohealth.com
